Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APLI |
---|---|---|
09:33 ET | 9000 | 0.03 |
11:05 ET | 8000 | 0.035 |
11:18 ET | 1000 | 0.035 |
11:21 ET | 273000 | 0.035 |
11:57 ET | 9000 | 0.035 |
12:15 ET | 20000 | 0.035 |
03:44 ET | 70000 | 0.035 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Appili Therapeutics Inc | 4.2M | -1.2x | --- |
Principal Technologies Inc | 5.9M | -2.1x | --- |
Revive Therapeutics Ltd | 4.2M | -0.7x | --- |
Awakn Life Sciences Corp | 5.0M | -1.2x | --- |
Innovotech Inc | 7.2M | -18.7x | --- |
Rakovina Therapeutics Inc | 5.4M | -1.3x | --- |
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2M |
---|---|
Revenue (TTM) | $494.8K |
Shares Outstanding | 121.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.95 |
EPS | $-0.03 |
Book Value | $-0.09 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 8.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,985.60% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.